NeuroPace, Inc. (NASDAQ:NPCE – Get Free Report) major shareholder Ltd. Kck sold 6,900 shares of the company’s stock in a transaction on Wednesday, October 16th. The shares were sold at an average price of $6.57, for a total transaction of $45,333.00. Following the sale, the insider now owns 5,510,957 shares of the company’s stock, valued at $36,206,987.49. The trade was a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Large shareholders that own at least 10% of a company’s stock are required to disclose their transactions with the SEC.
Ltd. Kck also recently made the following trade(s):
- On Monday, October 14th, Ltd. Kck sold 4,031 shares of NeuroPace stock. The stock was sold at an average price of $6.54, for a total transaction of $26,362.74.
- On Friday, October 11th, Ltd. Kck sold 2,572 shares of NeuroPace stock. The stock was sold at an average price of $6.35, for a total value of $16,332.20.
- On Wednesday, October 9th, Ltd. Kck sold 3,123 shares of NeuroPace stock. The shares were sold at an average price of $6.10, for a total value of $19,050.30.
- On Monday, October 7th, Ltd. Kck sold 4,910 shares of NeuroPace stock. The stock was sold at an average price of $6.66, for a total value of $32,700.60.
- On Thursday, October 3rd, Ltd. Kck sold 3,318 shares of NeuroPace stock. The shares were sold at an average price of $6.97, for a total transaction of $23,126.46.
NeuroPace Stock Up 1.3 %
NeuroPace stock opened at $6.47 on Friday. NeuroPace, Inc. has a 1-year low of $5.73 and a 1-year high of $18.15. The firm has a 50 day simple moving average of $7.05 and a 200 day simple moving average of $8.38. The company has a current ratio of 6.37, a quick ratio of 5.47 and a debt-to-equity ratio of 5.97. The firm has a market capitalization of $186.13 million, a price-to-earnings ratio of -5.44 and a beta of 1.78.
Analyst Ratings Changes
A number of equities research analysts have issued reports on NPCE shares. Morgan Stanley reduced their price objective on shares of NeuroPace from $9.50 to $8.00 and set an “equal weight” rating on the stock in a research note on Monday, July 15th. Cantor Fitzgerald restated an “overweight” rating and set a $18.00 price target on shares of NeuroPace in a report on Wednesday, August 14th. Finally, Wells Fargo & Company dropped their price objective on shares of NeuroPace from $20.00 to $15.00 and set an “overweight” rating for the company in a report on Wednesday, August 14th. One equities research analyst has rated the stock with a hold rating and six have assigned a buy rating to the stock. According to data from MarketBeat.com, NeuroPace has an average rating of “Moderate Buy” and an average target price of $14.00.
Get Our Latest Stock Analysis on NeuroPace
Hedge Funds Weigh In On NeuroPace
Large investors have recently added to or reduced their stakes in the business. Financial Advocates Investment Management raised its holdings in NeuroPace by 50.0% during the 2nd quarter. Financial Advocates Investment Management now owns 15,000 shares of the company’s stock valued at $113,000 after buying an additional 5,000 shares during the last quarter. XTX Topco Ltd raised its stake in NeuroPace by 56.1% during the second quarter. XTX Topco Ltd now owns 24,055 shares of the company’s stock valued at $182,000 after buying an additional 8,643 shares during the last quarter. Hillsdale Investment Management Inc. purchased a new stake in NeuroPace during the 1st quarter valued at about $155,000. Rhumbline Advisers bought a new position in shares of NeuroPace in the second quarter worth approximately $111,000. Finally, Acadian Asset Management LLC boosted its stake in NeuroPace by 46.0% during the 2nd quarter. Acadian Asset Management LLC now owns 68,918 shares of the company’s stock valued at $520,000 after purchasing an additional 21,703 shares during the last quarter. Hedge funds and other institutional investors own 78.83% of the company’s stock.
NeuroPace Company Profile
NeuroPace, Inc operates as a medical device company in the United States. The company develops RNS system, a brain-responsive neuromodulation system that delivers personalized, real-time treatment at the seizure source for treating medically refractory focal epilepsy. It also records continuous brain activity data and enables clinicians to monitor patients in person and remotely.
Featured Articles
- Five stocks we like better than NeuroPace
- What is Forex and How Does it Work?
- Misses and Beats: 3 Stocks That Are Moving Markets Right Now
- How to Calculate Retirement Income: MarketBeat’s Calculator
- Cisco on the Rise: AI Potential and Analyst Upgrades Drive Gains
- Are These Liquid Natural Gas Stocks Ready For An Upside Bounce?
- MarketBeat Week in Review – 10/14 – 10/18
Receive News & Ratings for NeuroPace Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NeuroPace and related companies with MarketBeat.com's FREE daily email newsletter.